These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26592960)

  • 1. Monitoring of dipeptidyl peptidase-IV (DPP-IV) activity in patients with mucopolysaccharidoses types I and II on enzyme replacement therapy - Results of a pilot study.
    Hetmańczyk K; Bednarska-Makaruk M; Kierus K; Murawska-Izdebska S; Piekutowska-Abramczuk D; Pilch B; Tylki-Szymańska A; Ługowska A
    Clin Biochem; 2016 Apr; 49(6):458-462. PubMed ID: 26592960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a new biomarker for the mucopolysaccharidoses (MPS), dipeptidyl peptidase IV (DPP-IV; CD26), by SELDI-TOF mass spectrometry.
    Beesley CE; Young EP; Finnegan N; Jackson M; Mills K; Vellodi A; Cleary M; Winchester BG
    Mol Genet Metab; 2009 Apr; 96(4):218-24. PubMed ID: 19153055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
    Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
    Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses.
    Jones SA; Marsden D; Koutsoukos T; Sniadecki J; Tylee K; Phillippo S; Kakkis E
    Mol Genet Metab; 2020 Aug; 130(4):255-261. PubMed ID: 32563631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum dipeptidyl peptidase-IV: a better screening test for early detection of mucopolysaccharidosis?
    Kurt I; Sertoglu E; Okur I; Tapan S; Uyanık M; Kayadıbı H; Ezgu FS; Aydın HI; Hasanoglu A
    Clin Chim Acta; 2014 Apr; 431():250-4. PubMed ID: 24582858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
    Miebach E
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S100-6. PubMed ID: 20040319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II.
    Wang RY; Cambray-Forker EJ; Ohanian K; Karlin DS; Covault KK; Schwartz PH; Abdenur JE
    Mol Genet Metab; 2009 Dec; 98(4):406-11. PubMed ID: 19748810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional capacity evaluation of patients with mucopolysaccharidosis.
    Guarany NR; Schwartz IV; Guarany FC; Giugliani R
    J Pediatr Rehabil Med; 2012; 5(1):37-46. PubMed ID: 22543891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation.
    Jacques CE; Donida B; Mescka CP; Rodrigues DG; Marchetti DP; Bitencourt FH; Burin MG; de Souza CF; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2016 Sep; 1862(9):1608-16. PubMed ID: 27251652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis.
    Matsubara Y; Miyazaki O; Kosuga M; Okuyama T; Nosaka S
    Pediatr Radiol; 2017 Nov; 47(12):1659-1669. PubMed ID: 28733853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
    Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
    PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study.
    Sestito S; Rinninella G; Rampazzo A; D'Avanzo F; Zampini L; Santoro L; Gabrielli O; Fiumara A; Barone R; Volpi N; Scarpa M; Tomanin R; Concolino D
    Orphanet J Rare Dis; 2022 Jun; 17(1):251. PubMed ID: 35768874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
    Nan H; Park C; Maeng S
    Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633
    [No Abstract]   [Full Text] [Related]  

  • 14. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
    Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
    Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.
    Tylki-Szymańska A; Almássy Z; Christophidou-Anastasiadou V; Avdjieva-Tzavella D; Barisic I; Cerkauskiene R; Cuturilo G; Djiordjevic M; Gucev Z; Hlavata A; Kieć-Wilk B; Magner M; Pecin I; Plaiasu V; Samardzic M; Zafeiriou D; Zaganas I; Lampe C
    Orphanet J Rare Dis; 2022 Mar; 17(1):136. PubMed ID: 35331284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic biomonitoring in mucopolyssacharosis I, II and IV patients treated with enzyme replacement therapy.
    Guilheiro JM; Chaves MD; Martins AM; Ribeiro DA; D'Almeida V
    Toxicol Mech Methods; 2014 Dec; 24(8):603-7. PubMed ID: 25141890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of gold nanoparticle-based real-time colorimetric assay of dipeptidyl peptidase IV activity.
    Aldewachi HS; Woodroofe N; Turega S; Gardiner PHE
    Talanta; 2017 Jul; 169():13-19. PubMed ID: 28411801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses.
    Frawley G; Fuenzalida D; Donath S; Yaplito-Lee J; Peters H
    Paediatr Anaesth; 2012 Aug; 22(8):737-44. PubMed ID: 22381044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
    Kim S; Whitley CB; Jarnes Utz JR
    Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.